CN Patent

CN111265651A — 补体c3抑制剂cp40-kk在制备防治肺动脉高压病药物中的应用

Assigned to Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology · Expires 2020-06-12 · 6y expired

What this patent protects

本发明公开了一种补体C3抑制剂CP40‑KK在制备防治肺动脉高压病药物中的应用；本发明中CP40‑KK能够通过抑制野百合碱诱导肺动脉高压模型大鼠肺动脉管腔缩小及管壁增厚。治疗性研究结果显示，CP40‑KK具有显著抑制肺动脉管腔缩小及管壁增厚、降低右室收缩压力、降低右室重量与左室加室间隔重量比值的疗效。

USPTO Abstract

本发明公开了一种补体C3抑制剂CP40‑KK在制备防治肺动脉高压病药物中的应用；本发明中CP40‑KK能够通过抑制野百合碱诱导肺动脉高压模型大鼠肺动脉管腔缩小及管壁增厚。治疗性研究结果显示，CP40‑KK具有显著抑制肺动脉管腔缩小及管壁增厚、降低右室收缩压力、降低右室重量与左室加室间隔重量比值的疗效。

Drugs covered by this patent

Patent Metadata

Patent number: CN111265651A
Jurisdiction: CN
Classification: —
Expires: 2020-06-12
Drug substance claim: No
Drug product claim: No
Assignee: Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.